Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
IMMUCELL CORP /DE/
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-85.1% vs price
Base Case (Median)
-81.1% vs price
Bull Case (75th pct.)
-39.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $7.24 | -26.5% | High (40%) |
| PE Comparable | $1.55 | -84.3% | Medium (25%) |
| Graham Number | $2.17 | -78.0% | Medium (40%) |
| EV/EBITDA | $1.45 | -85.3% | Medium (20%) |
| EV/FCF | $8.26 | -16.1% | Medium (20%) |
| Earnings Power Value | $1.15 | -88.3% | Medium (50%) |
Based on 6 out of 7 methods, ICCC appears overvalued at the current price of $9.85. The base case fair value of $1.86 implies 81.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.